



**EUCOPE**

European Confederation of  
Pharmaceutical Entrepreneurs AISBL

**Transfer of Voting Rights (Proxy)  
- EUCOPE General Meeting 21 June 2023 -**

I, \_\_\_\_\_,  
(name of person)

representing \_\_\_\_\_,  
(company name)

hereby transfer my voting rights for the above mentioned meeting

to \_\_\_\_\_,  
(name of person)

representing \_\_\_\_\_.  
(company name)

to execute my voting rights as indicated below:

1. Approval of the financial accounts for the preceding year (2022) as laid down in Annex I
  - Yes
  - No
2. Exoneration of the present Executive Board and the Secretary General
  - Yes
  - No
3. Approval of the budget of EUCOPE for the ongoing financial year (2023) as laid down in Annex I
  - Yes
  - No
4. Election of the Executive Board (Annex II):
  - I agree to the composition of the Executive Board as laid down in the Board recommendation of 14 February 2023:
    1. Jan G. Smith (ABIGO Medical), Chairman
    2. Diego Ardigò (Chiesi), Vice-Chairman
    3. Toon Digneffe (Takeda), Vice-Chairman



4. Leslie Galloway (EMIG – Ethical Medicines Industry Group), Vice-Chairman
5. Ben Gannon (Myriad)
6. Rüdiger Gatermann (CSL Behring), Vice-Chairman
7. Gunther Herr (Biologische Heilmittel Heel)
8. Christian Hill (MapBiopharma)
9. Kai Joachimsen (BPI)
10. Peter Martin (Norgine)
11. Konstantinos Panagoulas (VIANEX), Treasurer
12. André Zöller (Vertex)

- I do not agree to the recommendation but vote for the following people (please also indicate your vote for the chairman, vice-chairmen and treasurer)

1. \_\_\_\_\_
2. \_\_\_\_\_
3. \_\_\_\_\_
4. \_\_\_\_\_
5. \_\_\_\_\_
6. \_\_\_\_\_
7. \_\_\_\_\_
8. \_\_\_\_\_
9. \_\_\_\_\_
10. \_\_\_\_\_
11. \_\_\_\_\_
12. \_\_\_\_\_

5. I agree to the amendments to the increase of the EUCOPE Membership Fees as laid down in Annex III

- Yes
- No

\_\_\_\_\_  
(place, date)

\_\_\_\_\_  
(signature)



## Annex I

### Agenda Item 1: Approval of the financial accounts for the preceding year (2022)

	Planning GM 2022	Balance of Accounts 2022
EARNINGS	EUR 1,990,792	EUR 2,360,240
EXPENDITURES	EUR 1,633,947	EUR 2,133,957
<b>RESULT - INCOME</b>	<b>EUR 376,845</b>	<b>EUR 226,283</b>

### Agenda Item 3: Approval of the budget of EUCOPE for the ongoing financial year (2023)

	PLANNING 2023
EARNINGS	EUR 2,357,000
EXPENDITURES	EUR 2,329,880
<b>RESULT - INCOME</b>	<b>EUR 27,120</b>



**EUCOPE**

European Confederation of  
Pharmaceutical Entrepreneurs AISBL

## Annex II

### Agenda Item 4: Election of the Executive Board

#### List of Candidates

Twelve Board seats are available.

The Board of EUCOPE recommends the General Meeting the following people as Board Members from 1 July 2023 to 30 June 2026 (the recommendation is not binding and members can vote on all individual candidates out of I.-II.):

#### **I. Recommendation of the EUCOPE Board to the General Meeting of 14 February 2023**

1. Jan G. Smith  
(ABIGO Medical)  
**Chairman**

2. Diego Ardigò  
(Chiesi)  
**Vice-Chairman**

3. Toon Digneffe  
(Takeda)

4. Leslie Galloway  
(EMIG – Ethical Medicines Industry Group)  
**Vice-Chairman**

5. Ben Gannon  
(Myriad)

6. Rüdiger Gatermann  
(CSL Behring)  
**Vice-Chairman**

7. Gunther Herr  
(Biologische Heilmittel Heel)

8. Christian Hill  
(MapBiopharma)



**EUCOPE**

European Confederation of  
Pharmaceutical Entrepreneurs AISBL

9. Kai Joachimsen  
(BPI)

10. Peter Martin  
(Norgine)

11. Konstantinos Panagoulas  
(VIANEX)  
**Treasurer**

12. André Zöller  
(Vertex)

## **II. Additional Candidates for the Board**

The following people have also expressed their interest to become a Board Member:

13. Thomas Bols  
(PTC)

14. Brigitte Calles  
(Ferring)

15. Rachel Finnegan  
(BioMarin)

16. Maren v. Fritschen  
(Moderna)

17. Jörg Plessl  
(Norgine)



## Annex III

### Agenda Item 5: Increase of the EUCOPE Membership Fees as of 1 January 2024

#### 1. Background and Rationale

- The last adjustment of the membership fees was decided by the General Meeting in 2016.
- Since then, EUCOPE has further established itself as a key industry stakeholder for the innovative biopharmaceutical industry in Brussels and beyond.
- In order to achieve this position and to meaningfully support members, EUCOPE staff has grown from four people in 2016 to 10 in 2023. Additional services are performed through external service providers.
- EUCOPE's growth was possible through a continuous increase of the number of members **but now also requires an adjustment of the membership fees.**
- The ongoing legislative procedures regarding the General Pharmaceutical Legislation/OMP will require additional staff which will be facilitated by an increase of the fees.
- Obviously, also the general increases in prices have an impact of EUCOPE's budget (salaries, energy bills, thought-leadership events, costs for external service providers etc.). For example, the Belgian system of automatic indexation of the salaries of employees (reflecting the cost of living but also to the development of tax scales) required in 2022 alone four increases of altogether 8 %.
- **Therefore, it is suggested to increase the membership fees for the current two top tiers of company memberships.**
- **In addition, it is suggested to introduce a further tier for companies with a global turnover above 5 billion.**

#### 2. Suggested Membership Fee Structure (Approved by the EUCOPE Board on 14 February 2023)

Annual Turnover	2016-2022	2023
Up to EUR 10 million	EUR 5,000 p.a.	EUR 5,000 p.a. (no change)
> EUR 10 million	EUR 7,500 p.a.	EUR 7,500 p.a. (no change)
> EUR 50 million	EUR 12,000 p.a.	EUR 15,000 p.a. (+3,000 EUR)
> EUR 500 million	EUR 18,000 p.a.	EUR 24,000 p.a. (+6,000 EUR)
> EUR 5 billion	n/a	EUR 28,000 p.a. (+10,000 EUR)
Association with 200+ members	EUR 18,000 p.a.	EUR 18,000 p.a. (no change)
Associate Members	EUR 7,500 p.a.	EUR 7,500 p.a. (no change)